Floatz logo

Trilaciclib

Chemotherapy-Induced Toxicity

G1 Therapeutics, Inc.Small moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

66 Active assets in the Chemotherapy-Induced Toxicity cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4A
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Trilaciclib is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
myelosuppression, non-human animalDormant
B
Indicative ·
60 / 100
View asset →
Myelosuppression-AdultDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →